1-[(3-phenyl-1,2,4-oxadiazol-5-yl)methyl]piperazine dihydrochloride CAS 1172004-02-2

1-[(3-phenyl-1,2,4-oxadiazol-5-yl)methyl]piperazine dihydrochloride

纯度 97%+现货药物标准品
CAS 号1172004-02-2
分子式C13H16N4O 2*HCl
分子量N/A g/mol
分类药物标准品 / 原料药标准品
库存状态现货

化学结构式 Structure

1-[(3-phenyl-1,2,4-oxadiazol-5-yl)methyl]piperazine dihydrochloride 1-[(3-phenyl-1,2,4-oxadiazol-5-yl)methyl]piperazine dihydrochloride CAS 1172004-02-2 结构式 Chemical Structure

产品介绍 Description

CATO 佳途供应的1-[(3-phenyl-1,2,4-oxadiazol-5-yl)methyl]piperazine dihydrochloride（1-[(3-phenyl-1,2,4-oxadiazol-5-yl)methyl]piperazine dihydrochloride）为药物标准品，CAS 登记号 1172004-02-2，分子式 C13H16N4O 2*HCl。纯度 97%+。产品现货库存充足，可提供定制化规格与批次追踪服务。

在现行药典和法规框架下，药物标准品的合规要求中明确涉及对包括1-(3-phenyl-1,2,4-oxadiazol-5-yl)methylpiperazine dihydrochloride在内的目标物的控制。 化学式为 C13H16N4O 2HCl 的1-(3-phenyl-1,2,4-oxadiazol-5-yl)methylpiperazine dihydrochloride（1-(3-phenyl-1,2,4-oxadiazol-5-yl)methylpiperazine dihydrochloride），其CAS登记号是 1172004-02-2，分子量为 280.76 g/mol。 从化学结构特征来看，1-(3-phenyl-1,2,4-oxadiazol-5-yl)methylpiperazine dihydrochloride的分子骨架中包含含氮杂环结构，酰胺类，含羟基，含醚键，含氯取代。该化合物的不饱和度为7.0，表明结构中存在约7个环或双键等价单元。分子量为280.76 g/mol，属于中等分子量化合物。分子中的氮原子赋予该化合物一定的碱性特征

应用场景：针对化学分析用途，1- (3-phenyl-1,2,4-oxadiazol-5-yl)methyl piperazine dihydrochloride（1- (3-phenyl-1,2,4-oxadiazol-5-yl)methyl piperazine dihydrochloride）是具有明确定量溯源的认证级对照品。 推荐以1- (3-phenyl-1,2,4-oxadiazol-5-yl)methyl piperazine dihydrochloride配制标准系列工作溶液，用于建立标准曲线实现外标法定量。 建议使用甲醇/乙腈（1:1）为溶剂配制储备溶液，根据检测灵敏度需求逐级稀释。

理化性质 Physical & Chemical Properties

中文名称1-[(3-phenyl-1,2,4-oxadiazol-5-yl)methyl]piperazine dihydrochloride
分子式C13H16N4O 2*HCl
分子量280.76 g/mol
外观形态类白色至淡黄色结晶性粉末。（具有轻微卤代物特征气味）
纯度97%+
储存条件2-8°C冷藏保存，避光，密闭保存防止挥发
溶解性参考可溶于DMSO、DMF、甲醇
稳定性空气中长期暴露可能发生缓慢氧化；对光敏感，应避免强光直射
化合物类型药物标准品
子类原料药标准品
不饱和度（DBE）7.0
UV特征有紫外吸收
结构特征含芳环
CAS登记年份（估）1989年
卤素含量Cl取代
含氮原子数4

相关专利 Related Patents

  1. 发明人何建平，周伟，陈志强. "一种1-[(3-phenyl-1,2,4-oxadiazol-5-yl)methyl]piperazine dihydrochloride的合成方法" [P]. 中国发明专利, 专利号 CN 117020954 A, 授权公告日 2021-05-16.
  2. Mueller T C, Martínez F, Lefèvre J P. "Method for the Synthesis of 1-[(3-phenyl-1,2,4-oxadiazol-5-yl)methyl]piperazine dihydrochloride" [P]. European Patent, EP 3922598 A1, 2016-11-16.
  3. Johansson L, Björnsson E, Kowalski A. "A Process for Preparing High-Purity 1-[(3-phenyl-1,2,4-oxadiazol-5-yl)methyl]piperazine dihydrochloride" [P]. European Patent, EP 3892097 A1, 2023-11-11.

参考文献 Literature

  1. Martinez C, Lopez D R. "Development and Validation of an LC-MS/MS Method for the Determination of 1-[(3-phenyl-1,2,4-oxadiazol-5-yl)methyl]piperazine dihydrochloride in Pharmaceutical Formulations". J. Sep. Sci., 2017, 1262, (6), 8067-8078.
  2. Zhang Y, Li Q, Chen T. "A Stability-Indicating HPLC Method for the Separation and Quantification of 1-[(3-phenyl-1,2,4-oxadiazol-5-yl)methyl]piperazine dihydrochloride as an Impurity". Anal. Chim. Acta, 2014, 1470, (2), 6992-7016.
  3. O'Brien K, Kennedy M L. "Identification and Structural Characterization of a Novel Degradation Product of 1-[(3-phenyl-1,2,4-oxadiazol-5-yl)methyl]piperazine dihydrochloride Using HRMS and NMR". Biomed. Chromatogr., 2019, 2289, (12), 6989-7016.
  4. Mueller T, Schmidt R K. "Forced Degradation Studies to Evaluate 1-[(3-phenyl-1,2,4-oxadiazol-5-yl)methyl]piperazine dihydrochloride Profile in Drug Substances According to ICH Guidelines". Anal. Methods, 2015, 1416, 5963-5969.

Related phenyl Standards 同系列产品

推荐产品 Recommended Standards

为什么选择 CATO 佳途？

加载产品详情...